Message from MNC’s Board Chair – May 2020


Message from the Chair – This New Year brings great anticipation for progress in the treatment of melanoma and skin cancers, like cutaneous squamous cell carcinoma (cSCC). We have been anxiously awaiting provincial listings for adjuvant therapies for melanoma – in particular the adjuvant (for stage III fully resected patients), targeted therapy combination of Dabrafenib and Trametinib, and the adjuvant immunotherapies – Pembrolizumab and Nivolumab.

Thank You to MNC Volunteers

We are so appreciative for our many volunteers at MNC. Without your dedication, we would not be able to deliver…

Here to Support You!

COVID-19 has created much uncertainty for our dear MNC friends, turning the world as we know it completely upside down.…


Sign up to receive the latest news from Melanoma Network of Canada